Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Opiant Pharmaceuticals Inc. (OPNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 13,464
  • Shares Outstanding, K 2,040
  • Annual Sales, $ 9,900 K
  • Annual Income, $ -7,810 K
  • 36-Month Beta N/A
  • Price/Sales 1.35
  • Price/Cash Flow 0.00
  • Price/Book 2.24
  • Price/Earnings ttm 1.54
  • Earnings Per Share ttm 4.24
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/21/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.3200 +4.43%
on 04/26/17
7.8800 -16.24%
on 03/29/17
-1.1500 (-14.84%)
since 03/28/17
3-Month
6.3200 +4.43%
on 04/26/17
9.0600 -27.15%
on 02/13/17
-1.7500 (-20.96%)
since 01/27/17
52-Week
5.0100 +31.74%
on 11/10/16
10.0000 -34.00%
on 05/04/16
-2.3000 (-25.84%)
since 04/28/16

Most Recent Stories

More News
Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has initiated a Phase 2 clinical...

OPNT : 6.6000 (+0.76%)
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN(R) Nasal Spray Patents

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that its most recently issued U.S. patents,...

OPNT : 6.6000 (+0.76%)
Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that the Company has received supportive feedback...

OPNT : 6.6000 (+0.76%)
Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the...

OPNT : 6.6000 (+0.76%)
Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the...

OPNT : 6.6000 (+0.76%)
Opiant Pharmaceuticals, Inc., Reports Fiscal First Quarter 2017 Financial Results and Provides Corporate Update

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today reported financial...

OPNT : 6.6000 (+0.76%)
Opiant Pharmaceuticals, Inc. Announces NARCAN(R) Nasal Spray Royalty Monetization

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that it...

OPNT : 6.6000 (+0.76%)
Opiant Pharmaceuticals, Inc. Announces Appointment of Thomas T. Thomas to Board of Directors

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the appointment...

OPNT : 6.6000 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Support & Resistance

2nd Resistance Point 6.7733
1st Resistance Point 6.6867
Last Price 6.6000
1st Support Level 6.5067
2nd Support Level 6.4133

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.